![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » GENEREX BIOTECHNOLOGY RECEIVES $6.4 MILLION FROM WARRANT EXERCISES
GENEREX BIOTECHNOLOGY RECEIVES $6.4 MILLION FROM WARRANT EXERCISES
October 31, 2005
Generex Biotechnology Corporation (Nasdaq: GNBT -- News) announced today that it has received, over the past two weeks, an aggregate of $6.4 million as a result of the exercise by existing Company investors of previously issued warrants. The receipt of these funds has put the Company in its strongest cash position in nearly two years.
Yahoo News (http://biz.yahoo.com/prnews/051028/nyf078.html?.v=27)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct